Type 1 diabetes concept suggested by insulin syringe] adrian825 Vertex Pharmaceuticals (NASDAQ:VRTX [ has posted new data from a Phase 1/2/3 study for zimislecel (VX-880), its experimental therapy for ...

Angelo Libertucci, global head of industry for telecom at Google Cloud, discusses the hyperscaler’s recently unveiled ...

Google Gemini is making waves in 2025 with advanced AI tools built to support entrepreneurs and small business owners. This ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Large Cap Equity Strategy” ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 ...

But NICE rejected Vertex’s CF latest drug Orkambi for routine NHS funding in final guidance published in July 2016, saying the drug’s £104,000 per year price tag was too expensive.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

How to show more historical data? Use the zoom-out option. You can add up to 100 technical indicators to your graph, such as Linear Regression, CCI, ADX, and many more. In our commitment to ...

Dexcom's Stelo is an over-the-counter continuous glucose monitor that leverages AI-driven insights to help you track, evaluate, and manage your metabolic health.